Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple Sclerosis.

Annals of neurology·2026
Same author

Clinical and radiological outcomes of directed treatment transitions from Gilenya<sup>®</sup> to generic fingolimod.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Inebilizumab: Pediatric Case Series in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder.

Pediatric neurology·2025
Same author

First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trial.

EBioMedicine·2025
Same author

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.

Journal of neurology·2025
Same author

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Neurology(R) neuroimmunology & neuroinflammation·2025

Related Experiment Video

Updated: Jul 7, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Future research directions in multiple sclerosis therapies.

Benjamin M Greenberg1, Peter A Calabresi

  • 1Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.

Seminars in Neurology
|February 8, 2008
PubMed
Summary

New multiple sclerosis (MS) therapies aim for better efficacy and fewer side effects. Research focuses on targeted immunotherapies and neuroprotection to address MS complexity.

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Experiment Videos

Last Updated: Jul 7, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Area of Science:

  • Neuroimmunology
  • Multiple Sclerosis Therapeutics

Background:

  • Current injectable immunomodulatory therapies for multiple sclerosis (MS) have driven interest in improved treatments.
  • Oral agents and monoclonal antibodies show promise in clinical trials, but target non-specific immune molecules with potential side effects.

Purpose of the Study:

  • To explore novel immunotherapies with selective targeting of pathogenic cells.
  • To investigate strategies for inducing self-protein tolerance in MS.
  • To understand and modulate nonclassical immune targets and central nervous system degenerative processes in MS.

Main Methods:

  • Review of current and emerging therapeutic strategies for multiple sclerosis.
  • Analysis of preclinical and early-phase clinical trial data for novel immunotherapies.
  • Examination of research into neurodegenerative mechanisms and potential neuroprotective agents in MS.

Main Results:

  • Several oral agents and monoclonal antibodies are advancing to phase III trials.
  • Novel immunotherapies aim for selective targeting of immune cells to minimize systemic side effects.
  • Research is expanding to include neuroprotection and modulation of nonclassical immune targets.

Conclusions:

  • The field is moving towards more targeted and potentially better-tolerated therapies for MS.
  • Addressing multifactorial neurodegeneration alongside immune modulation is crucial for MS treatment.
  • Future MS therapies may integrate immunomodulation with neuroprotective strategies.